The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis

Recruiting

You are on the General Public view
  • Source

    -
    Public Title The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis
    Acronym SABRE
    Source of Record URL http://clinicaltrials.gov/show/NCT01469845
  • Trial

    -
    Health Condition(s) or Problem Acute Bronchiolitis
    Lay Summary Acute bronchiolitis is a common, distressing illness affecting children. A virus infects the lungs, and then the airways become blocked, leading to difficulties with breathing. It is the most common reason why children are admitted to hospital, with 1-3% of all children admitted to hospital during their first winter, creating enormous strains on NHS services. The majority of those admitted with the condition are under six months of age and the associated stress for parents is considerable. After forty years of research the best treatment we have is supportive care and oxygen. Recent research suggests that salt water, sprayed as a mist so that the children can breathe it in ('nebulised 3% hypertonic saline') might help children with acute bronchiolitis. Scientists think that the salt water changes the mucus which blocks the airways so that it can be cleared more easily. Three small research studies all suggested that a child's time in hospital could be reduced by a quarter by using this treatment. If this was true, it would be good for children, their families and the children's wards trying to cope with the large numbers admitted with bronchiolitis every year. To decide whether this treatment should be used throughout the NHS, we need to run a randomised controlled trial of hypertonic saline in a large number of children. The trial will tell us if adding saline to usual care reduces distress in both children and parents, as well as whether it reduces the length of time they stay in hospital. We will then know if the treatment is the best thing for children with bronchiolitis and whether it provides the NHS with good value for money. (from ClinicalTrials.gov)
    Who can enter the trial Inclusion Criteria: - Previously healthy infants under 1 year of age - Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation - Requiring supplemental oxygen therapy on admission Exclusion Criteria: - Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations - Previous lower respiratory tract infections - Risk factors for severe disease [gestation <32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease] - Subjects where the carer's English is not fluent and translational services are not available - Requiring admission to high dependency or intensive care units at the time of recruitment
    Who cannot enter the trial Inclusion Criteria: - Previously healthy infants under 1 year of age - Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation - Requiring supplemental oxygen therapy on admission Exclusion Criteria: - Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations - Previous lower respiratory tract infections - Risk factors for severe disease [gestation <32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease] - Subjects where the carer's English is not fluent and translational services are not available - Requiring admission to high dependency or intensive care units at the time of recruitment
    What will happen Device; 3% hypertonic saline; 4 ml dose to be administered every 6 hours; hypertonic saline and usual care; usual care (oxygen therapy); mucoclear 3%
    Primary aim Time to 'fit for discharge', which will be judged to be when the infant is feeding adequately [taking >75% of usual intake] and has been in air with a saturation of at least 92% for 6 hours, to reflect clinical practice.
    Secondary Aim Actual time to discharge; No; Readmission; Within 28 days from randomisation; Yes; health care utilisation; post-discharge and within 28 days from randomisation; Yes; duration of respiratory symptoms; post discharge and within 28 days from randomisation; Yes; Infant and parental quality of life using the Infant Toddler Quality of Life (ITQoL) questionnaire; 28 days following randomisation.; No
    Participant Information Sheet Sorry, not currently available
    Website http://www.shef.ac.uk/scharr/sabre; http://www.hta.ac.uk
    Recruitment Status Recruiting
    Nation England, Wales
    Location Liverpool, Stoke-on-Trent, Cardiff, Doncaster, Rotherham, Sheffield, Bradford, Halifax, Leeds
  • Contact

    -
    Contact for Public Queries Mark L Everard, DM 0044 114 271 7400 m.l.everard@sheffield.ac.uk
    Contact for Scientific Queries Paul McNamara; Principal Investigator; John Alexander; Principal Investigator; Colin Powell; Principal Investigator; Mathew Kurian; Principal Investigator; Peter Macfarlane; Principal Investigator; Heather Elphick; Principal Investigator; Eduardo Moya; Principal Investigator; Jonathan Garside; Principal Investigator; Philip Chetcuti; Principal Investigator
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.